Huot C, Tremblay J, Hamet P
Clinical Research Institute of Montreal, Canada.
Blood Vessels. 1991;28(1-3):84-92. doi: 10.1159/000158847.
Atrial natriuretic peptide (ANP) exhibits a wide spectrum of cardiovascular, endocrine, metabolic and renal actions. cGMP is the major mediator of ANP at the cellular level and only tissues possessing particulate guanylate cyclase appear to present ANP-induced actions. Three types of ANP receptors have recently been cloned. Two of them (A and B receptors) are homologous and contain guanylate cyclase catalytic domains. The C receptor could possibly regulate the metabolic fate of ANP. Data obtained by the radiation inactivation method suggest the presence of an inter- or intramolecular inhibitory component of nearly 90 kilodaltons that represses the catalytic activity of guanylate cyclase within its membrane environment. The mechanism of guanylate cyclase stimulation by ANP could involve this inhibitory component. Preliminary data suggest that the hyperresponsiveness of the particulate guanylate cyclase/cGMP system in hypertension occurs through modulation of the inhibitory component.
心房利钠肽（ANP）具有广泛的心血管、内分泌、代谢和肾脏作用。环磷酸鸟苷（cGMP）是ANP在细胞水平的主要介质，只有具有颗粒型鸟苷酸环化酶的组织似乎才会出现ANP诱导的作用。最近克隆出了三种类型的ANP受体。其中两种（A和B受体）是同源的，含有鸟苷酸环化酶催化结构域。C受体可能调节ANP的代谢命运。通过辐射失活法获得的数据表明，存在一种近90千道尔顿的分子间或分子内抑制成分，该成分在膜环境中抑制鸟苷酸环化酶的催化活性。ANP刺激鸟苷酸环化酶的机制可能涉及这种抑制成分。初步数据表明，高血压中颗粒型鸟苷酸环化酶/cGMP系统的高反应性是通过抑制成分的调节而发生的。
